Gilead Sciences Past Performance

Past criteria checks 4/6

Gilead Sciences has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 4.9% per year. Gilead Sciences's return on equity is 26.4%, and it has net margins of 20.6%.

Key information


Earnings growth rate


EPS growth rate

Biotechs Industry Growth44.3%
Revenue growth rate4.9%
Return on equity26.4%
Net Margin20.6%
Last Earnings Update31 Mar 2023

Recent past performance updates

Recent updates

Earnings and Revenue History

Quality Earnings: GIS has a large one-off loss of $2.2B impacting its last 12 months of financial results to March 31 2023.

Growing Profit Margin: GIS's current net profit margins (20.6%) are higher than last year (16.4%).

Past Earnings Growth Analysis

Earnings Trend: GIS's earnings have grown by 6.7% per year over the past 5 years.

Accelerating Growth: GIS's earnings growth over the past year (23.7%) exceeds its 5-year average (6.7% per year).

Earnings vs Industry: GIS earnings growth over the past year (23.7%) exceeded the Biotechs industry -12%.

Return on Equity

High ROE: Whilst GIS's Return on Equity (26.45%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies